Erik Hertervig

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013-2021.

A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013-2021.

Journal: Drug safety

Published: January 19, 2025

Endoscopic scoring of immune-mediated colitis disease activity.

Endoscopic scoring of immune-mediated colitis disease activity.

Journal: Gastrointestinal endoscopy

Published: October 03, 2024

A new Simple Endoscopic Score for Ulcerative Colitis - the SES-UC.

A new Simple Endoscopic Score for Ulcerative Colitis - the SES-UC.

Journal: Frontiers in gastroenterology (Lausanne, Switzerland)

Published: July 22, 2024

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.

Journal: Therapeutic advances in gastroenterology

Published: December 12, 2022

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: July 15, 2022

Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.

Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.

Journal: Scandinavian journal of gastroenterology

Published: August 20, 2021

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.

Journal: Therapeutic advances in gastroenterology

Published: March 12, 2021

Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study.

Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study.

Journal: Scandinavian journal of gastroenterology

Published: January 22, 2020

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.

Journal: Gastroenterology

Published: June 07, 2019

The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.

The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.

Journal: Journal of Crohn's & colitis

Published: March 21, 2019

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Journal: Therapeutic advances in gastroenterology

Published: June 15, 2018

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).

Journal: Scandinavian journal of gastroenterology

Published: April 01, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026